Login / Signup

Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) Associated with SARS-CoV-2 Infection: Post-Infectious Neurological Complication with Benign Prognosis.

Enrique Urrea-MendozaKimberly OkaforSenthuran RavindranJohn AbsherVarun ChaubalFredy J Revilla
Published in: Tremor and other hyperkinetic movements (New York, N.Y.) (2021)
The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) is the cause of the COVID-19 pandemic [5]. SARS-Cov-2 demonstrates partial resemblance to SARS-CoV and MERS-CoV in phylogenetic analysis, clinical manifestations, and pathological findings [6, 7]. Reports emerging from China have described ataxia as a neurological symptom of the SARS-CoV-2 infection [5]. Opsoclonus consists of back-to-back multidirectional conjugate saccades without an inter-saccadic interval [8]. Myoclonus is defined as a sudden, brief, "shock-like", nonepileptic involuntary movement [9], which has been described as a symptom of SARS-CoV-2 infection [10]. Opsoclonus-Myoclonus-Ataxia syndrome (OMAS) associated COVID-19 infection has been reported recently [1112].
Keyphrases
  • respiratory syndrome coronavirus
  • sars cov
  • early onset
  • coronavirus disease
  • case report
  • cerebral ischemia
  • patient reported
  • subarachnoid hemorrhage
  • adverse drug
  • blood brain barrier